-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the work arrangement issued by the National Organization of Drug Joint Purchasing Office on January 6, 2022, from May 2022, the results of the sixth batch of national centralized drug procurement (insulin special) will be officially implemented.
The specific implementation date is subject to the announcements issued by various places
.
At present, many places are preparing for the sixth batch of national harvest
.
For example, the Heilongjiang Central Drug Procurement Center recently issued a notice on the launch of the sixth batch of nationally organized centralized drug procurement (insulin special) related work related to the listing of selected drugs on the Internet, requiring relevant drug manufacturers to upload and submit the start and end time on February 18, 20229 From February 28th, all materials uploaded before the deadline can be withdrawn and modified, and they will not be able to operate after the deadline
.
The reported price should be the smallest unit price of the selected drug
.
In December 2021, Ningxia issued the "Notice on Carrying out the Selection of Amounts to be Distributed for Special Insulin Procurement in Medical Institutions", which clarified that the selection of the amount to be distributed in the sixth batch of nationally organized centralized drug procurement (special insulin) is about to begin
.
Gansu also issued the "Notice on Announcement of the Online Application Results of the Sixth Batch of Nationally Organized Centralized Drug Procurement (Insulin Special)" at the end of 2021, stating that after enterprise declaration and review by provincial drug procurement agencies, the sixth batch of national centralized drug procurement A total of 78 product specifications were declared online for the selected drugs (special insulin products)
.
It is believed that the province will officially list the results of the collection in the near future
.
In November 2021, the sixth batch of insulin special-purpose national procurement list was announced.
A total of 16 generic varieties of 11 companies were selected, with an average price reduction of nearly 50%.
Among them, Eli Lilly's protamine zinc recombinant insulin lispro mixed injection (25R ) dropped by 73.
76%, and Gan & Lee's insulin aspartate dropped by more than 70%
.
Among the 11 selected companies, several multinational pharmaceutical companies, including Novo Nordisk, Eli Lilly, Poland Baitong (the agent of Yifan Pharmaceutical), and Sanofi, are domestic companies.
.
From the results of the selection, domestic pharmaceutical companies performed outstandingly.
Among them, Gan & Lee Pharmaceuticals and United Laboratories both won the bids for 6 products, and Tonghua Dongbao, Hefei Tianmai, Dongyang Pharmaceutical, Jiangsu Wanbang and Hisun Pharmaceuticals won the bids respectively.
5, 3, 2, 2, 1, and basically the A-type or B-type bids are won, and the company will obtain a larger agreed purchase volume
.
Among multinational pharmaceutical companies, Novo Nordisk has won the bid for 7 products, Eli Lilly, Poland Baitong (the agent of Yifan Pharmaceutical), and Sanofi have 5, 3, and 2 selected products respectively
.
In the past, China's insulin market was mainly composed of Novo Nordisk, Eli Lilly, Sanofi, Gan & Lee Pharmaceutical, Tonghua Dongbao, and United Laboratories, and three multinational pharmaceutical companies occupied the main market share, accounting for more than 70%.
%
.
According to the analysis of research reports of many securities institutions, with the implementation of national procurement of insulin, the 25 billion market will undergo great changes, domestic substitution is expected to accelerate, and relevant companies with strength are expected to benefit
.
Following the announcement of the results of the sixth batch of national procurement, local pharmaceutical companies such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, and United Laboratories, which won the bid, also issued announcements stating that winning the bid for centralized procurement will help expand the sales of related products and increase the company's product market share.
rate
.
In addition, for the market that has not been included in the collection and reporting volume, Gan & Lee Pharmaceutical also plans to double the number of people in the current marketing team of 1,000 people, fully replace the second-generation insulin analogs with third-generation insulin analogs, and accelerate the improvement of various The penetration rate of products sinking into the grassroots market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The specific implementation date is subject to the announcements issued by various places
.
At present, many places are preparing for the sixth batch of national harvest
.
For example, the Heilongjiang Central Drug Procurement Center recently issued a notice on the launch of the sixth batch of nationally organized centralized drug procurement (insulin special) related work related to the listing of selected drugs on the Internet, requiring relevant drug manufacturers to upload and submit the start and end time on February 18, 20229 From February 28th, all materials uploaded before the deadline can be withdrawn and modified, and they will not be able to operate after the deadline
.
The reported price should be the smallest unit price of the selected drug
.
In December 2021, Ningxia issued the "Notice on Carrying out the Selection of Amounts to be Distributed for Special Insulin Procurement in Medical Institutions", which clarified that the selection of the amount to be distributed in the sixth batch of nationally organized centralized drug procurement (special insulin) is about to begin
.
Gansu also issued the "Notice on Announcement of the Online Application Results of the Sixth Batch of Nationally Organized Centralized Drug Procurement (Insulin Special)" at the end of 2021, stating that after enterprise declaration and review by provincial drug procurement agencies, the sixth batch of national centralized drug procurement A total of 78 product specifications were declared online for the selected drugs (special insulin products)
.
It is believed that the province will officially list the results of the collection in the near future
.
In November 2021, the sixth batch of insulin special-purpose national procurement list was announced.
A total of 16 generic varieties of 11 companies were selected, with an average price reduction of nearly 50%.
Among them, Eli Lilly's protamine zinc recombinant insulin lispro mixed injection (25R ) dropped by 73.
76%, and Gan & Lee's insulin aspartate dropped by more than 70%
.
Among the 11 selected companies, several multinational pharmaceutical companies, including Novo Nordisk, Eli Lilly, Poland Baitong (the agent of Yifan Pharmaceutical), and Sanofi, are domestic companies.
.
From the results of the selection, domestic pharmaceutical companies performed outstandingly.
Among them, Gan & Lee Pharmaceuticals and United Laboratories both won the bids for 6 products, and Tonghua Dongbao, Hefei Tianmai, Dongyang Pharmaceutical, Jiangsu Wanbang and Hisun Pharmaceuticals won the bids respectively.
5, 3, 2, 2, 1, and basically the A-type or B-type bids are won, and the company will obtain a larger agreed purchase volume
.
Among multinational pharmaceutical companies, Novo Nordisk has won the bid for 7 products, Eli Lilly, Poland Baitong (the agent of Yifan Pharmaceutical), and Sanofi have 5, 3, and 2 selected products respectively
.
In the past, China's insulin market was mainly composed of Novo Nordisk, Eli Lilly, Sanofi, Gan & Lee Pharmaceutical, Tonghua Dongbao, and United Laboratories, and three multinational pharmaceutical companies occupied the main market share, accounting for more than 70%.
%
.
According to the analysis of research reports of many securities institutions, with the implementation of national procurement of insulin, the 25 billion market will undergo great changes, domestic substitution is expected to accelerate, and relevant companies with strength are expected to benefit
.
Following the announcement of the results of the sixth batch of national procurement, local pharmaceutical companies such as Gan & Lee Pharmaceuticals, Tonghua Dongbao, and United Laboratories, which won the bid, also issued announcements stating that winning the bid for centralized procurement will help expand the sales of related products and increase the company's product market share.
rate
.
In addition, for the market that has not been included in the collection and reporting volume, Gan & Lee Pharmaceutical also plans to double the number of people in the current marketing team of 1,000 people, fully replace the second-generation insulin analogs with third-generation insulin analogs, and accelerate the improvement of various The penetration rate of products sinking into the grassroots market
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
